TABLE 1.

General characteristics of the included studies.

Study	Type of study	COVID-19 stage	Sample size (E/C)	Age (M ± SD) (E/C)	Treatment		Dose/Frequency (SFJD)	Durations
					Intervention	Control
Yan et al. (25)	RCT	Ordinary	50/50	60.26 ± 7.32/59.48 ± 8.24	SFJD + interferon alpha + arbidol	Interferon alpha + arbidol	2.08 g/times, tid	14 days
Zhang et al. (33)	RCT	Mild	117/117	41.7 ± 9.9/41.2 ± 13.9	SFJD + conventional therapy	Conventional therapy	2.08 g/times, tid	7 days
Chen et al. (30)	Cohort study	Ordinary	34/34	65.06 ± 10.63/64.35 ± 10.34	SFJD + conventional therapy	Conventional therapy	2.08 g/times, tid	7 days
Qu et al. (28)	Cohort study	Mild and ordinary	40/40	39.65 ± 11.20/41.60 ± 10.50	SFJD + arbidol + conventional therapy	Arbidol + Conventional therapy	2.08 g/times, tid	10 days
Wu et al. (27)	Case series	Ordinary	44	43.04 ± 15.33	SFJD + conventional therapy		2.08 g/times, tid	3–7 days
Chen et al. (32)	Cohort study	Ordinary	100/100	60.2 ± 6.6/60.4 ± 6.6	SFJD + arbidol	Arbidol	2.08 g/times, tid	14 days
Xia et al. (31)	Cohort study	Mild and ordinary	43/33	46.95 ± 14.9/45.9 ± 13.3	SFJD + antiviral drugs (umifenovir /lopinavir/ritonavir tablets)	Antiviral drugs (umifenovir/ lopinavir/ritonavir tablets)	2.08 g/times, tid	Within 3 week
Guo et al. (34)	Case series	Ordinary and severe	11	40.5 (13.5–66)	SFJD + antiviral drugs (abidor/umifenovir/lopinavir tablets)		/	/
Qu et al. (29)	Cohort study	Mild and ordinary	40/30	40.65 ± 8.23/39.82 ± 6.40	SFJD + arbidol + conventional therapy	Arbidol + conventional therapy	2.08 g/times, tid	10 days
Xiao et al. (26)	Non-RCT	Mild	100/100	69.90 ± 8.70/62.20 ± 7.50	SFJD + arbidol	Arbidol	2.08 g/times, tid	14 days

E, Experiment group; C, Control group; M, Mean; SD, Standard Deviation; SFJD, Shufeng Jiedu capsule; tid, three times a day; RCT, Randomized controlled trial.